Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul B Mehta

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Expert Opinion on Medical Diagnostics|October 17, 2013
Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?Alison S Thomas, Atul B Mehta
Hematology (Amsterdam, Netherlands)|June 16, 2001
Infusional 5-fluorouracil in Cutaneous Leukaemia: a Novel Palliative Therapy in Haematological Malignancy; MalignancyClare P. F. Taylor, Atul B. Mehta
European Journal of Pharmacology|March 17, 2009
Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activityGareth Gerrard, Terry D Butters, Kanagasabai Ganeshaguru, et al.
Journal of Inherited Metabolic Disease|October 6, 2011
Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T)Hatim Y Ebrahim, Robert J Baker, Atul B Mehta, et al.
Haematologica|September 13, 2005
Rituximab in the treatment of refractory autoimmune cytopenias in adultsSanthosh Narat, Jagdeesh Gandla, Allan Victor Hoffbrand, et al.
Molecular Genetics and Metabolism|June 24, 2018
Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher diseaseMatthew C Reed, Capucine Schiffer, Simon Heales, et al.
International Journal of Hematology|December 19, 2009
An unusual case of transient dermatological reaction to bortezomib in AL amyloidosisAnoop D Shah, Andrew J B Watts, Atul B Mehta, et al.
Molecular Genetics and Metabolism|October 23, 2017
The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfaDylan J Mac Lochlainn, Douglas G J McKechnie, Atul B Mehta, et al.
Hip International : the Journal of Clinical and Experimental Research on Hip Pathology and Therapy|November 22, 2011
Gaucher disease: outcome following total hip replacements and effect of enzyme replacement therapy in a cohort of UK patientsJames Donaldson, Wasim S Khan, Hiteshkumar Tailor, et al.
Gene|August 13, 2018
Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of diseaseMatthew C Reed, Yehudit Bauernfreund, Niamh Cunningham, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Expert Opinion on Medical Diagnostics|October 17, 2013
Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?Alison S Thomas, Atul B Mehta
Hematology (Amsterdam, Netherlands)|June 16, 2001
Infusional 5-fluorouracil in Cutaneous Leukaemia: a Novel Palliative Therapy in Haematological Malignancy; MalignancyClare P. F. Taylor, Atul B. Mehta
European Journal of Pharmacology|March 17, 2009
Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activityGareth Gerrard, Terry D Butters, Kanagasabai Ganeshaguru, et al.
Journal of Inherited Metabolic Disease|October 6, 2011
Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T)Hatim Y Ebrahim, Robert J Baker, Atul B Mehta, et al.
Haematologica|September 13, 2005
Rituximab in the treatment of refractory autoimmune cytopenias in adultsSanthosh Narat, Jagdeesh Gandla, Allan Victor Hoffbrand, et al.
Molecular Genetics and Metabolism|June 24, 2018
Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher diseaseMatthew C Reed, Capucine Schiffer, Simon Heales, et al.
International Journal of Hematology|December 19, 2009
An unusual case of transient dermatological reaction to bortezomib in AL amyloidosisAnoop D Shah, Andrew J B Watts, Atul B Mehta, et al.
Molecular Genetics and Metabolism|October 23, 2017
The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfaDylan J Mac Lochlainn, Douglas G J McKechnie, Atul B Mehta, et al.
Hip International : the Journal of Clinical and Experimental Research on Hip Pathology and Therapy|November 22, 2011
Gaucher disease: outcome following total hip replacements and effect of enzyme replacement therapy in a cohort of UK patientsJames Donaldson, Wasim S Khan, Hiteshkumar Tailor, et al.
Gene|August 13, 2018
Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of diseaseMatthew C Reed, Yehudit Bauernfreund, Niamh Cunningham, et al.
Pageof 3